Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 270 across all filing types
Latest filing 2025-04-02 Proxy Solicitation & In…
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a combined Notice of Annual Meeting and detailed Management Information Circular soliciting proxy votes for unitholders, including background on voting procedures, proposals (elect trustees, appoint auditors, advisory vote on compensation), corporate governance, executive compensation discussion, and related schedules. This matches the definition of a Proxy Solicitation & Information Statement (PSI), as it provides materials sent to unitholders to request votes for the meeting. It is not merely an announcement of a report, not an annual report itself, nor an earnings release. Therefore, the correct classification is PSI.
2025-04-02 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a debt settlement agreement by issuing common shares (1,200,000 shares at $0.05) to a lender to settle $60,000 of debt. This is a financing transaction and a change in capital structure. It is not an earnings release, management change, or AGM material, but clearly an update on financing activity. Therefore, it should be classified under Capital/Financing Update (CAP).
2025-04-02 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a NI 52-109 Venture Issuer Basic Certificate—a regulatory attestation by the CEO certifying the review and fair presentation of annual filings under Canadian securities rules. It is not the Annual Report itself (10-K) nor an Earnings Release, Management Discussion & Analysis, or any change announcement. It is a stand-alone regulatory certificate filing and thus falls under the fallback category “Regulatory Filings (RNS).”
2025-03-19 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV1 “Venture Issuer Basic Certificate” signed by the CFO under NI 52-109 certifying the annual filings (AIF, financial statements, MD&A) for the fiscal year. It is not the actual annual report, audit report, MD&A, or earnings release, nor is it an AGM presentation, voting announcement, or capital transaction. Instead, it is a mandated regulatory certificate filed with securities regulators, which falls under the general Regulatory Filings category (RNS).
2025-03-19 English
Annual MD&A - English.pdf
Regulatory Filings
2025-03-19 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 0% confidence The document is a corporate news release from Pelangio Exploration Inc. announcing a delay in the Mineral Resource Estimate (MRE) release due to a strategic acquisition. It is not a financial report (Annual or Interim), not a call transcript, not a dividend or share issuance notice, nor a management or governance filing. It is a general press release/regulatory announcement that does not fit any more specific category, therefore it falls into the fallback category for miscellaneous regulatory announcements (RNS).
2025-03-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.